Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2009 1
2012 1
2013 1
2014 6
2015 20
2016 50
2017 70
2018 97
2019 110
2020 170
2021 207
2022 188
2023 166
2024 173
2025 130

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Geographic differences in heart failure trials.
Ferreira JP, Girerd N, Rossignol P, Zannad F. Ferreira JP, et al. Eur J Heart Fail. 2015 Sep;17(9):893-905. doi: 10.1002/ejhf.326. Epub 2015 Jul 21. Eur J Heart Fail. 2015. PMID: 26198782 Free article. Review.
The double challenge of resistant hypertension and chronic kidney disease.
Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D; ERA-EDTA EURECA-m working group; Red de Investigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network. Rossignol P, et al. Lancet. 2015 Oct 17;386(10003):1588-98. doi: 10.1016/S0140-6736(15)00418-3. Lancet. 2015. PMID: 26530623 Review.
New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronic kidney disease. ...
New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investiga …
Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity.
Martínez-Martínez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé MV, Fernández-Celis A, Rossignol P, Islas F, Antequera A, Prieto S, Luaces M, Cachofeiro V. Martínez-Martínez E, et al. Hypertension. 2015 Nov;66(5):961-9. doi: 10.1161/HYPERTENSIONAHA.115.06032. Epub 2015 Sep 8. Hypertension. 2015. PMID: 26351031
Galectin-3 (Gal-3) induces inflammation and fibrosis in the cardiovascular system. We have investigated the potential role of Gal-3 in cardiac damage in morbidly obese patients, and we have evaluated the protective effect of the Gal-3 inhibition in the occurr …
Galectin-3 (Gal-3) induces inflammation and fibrosis in the cardiovascular system. We have investigated the potential r …
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N. Calvier L, et al. JACC Heart Fail. 2015 Jan;3(1):59-67. doi: 10.1016/j.jchf.2014.08.002. Epub 2014 Nov 11. JACC Heart Fail. 2015. PMID: 25458174 Free article.
OBJECTIVES: This study investigated whether galectin (Gal)-3 inhibition could block aldosterone-induced cardiac and renal fibrosis and improve cardiorenal dysfunction. ...In wild-type mice, aldosterone did not alter blood pressure levels but increased cardiac and …
OBJECTIVES: This study investigated whether galectin (Gal)-3 inhibition could block aldosterone-induced cardiac and renal fibr …
Prognostic Value of Estimated Plasma Volume in Heart Failure.
Duarte K, Monnez JM, Albuisson E, Pitt B, Zannad F, Rossignol P. Duarte K, et al. JACC Heart Fail. 2015 Nov;3(11):886-93. doi: 10.1016/j.jchf.2015.06.014. JACC Heart Fail. 2015. PMID: 26541787 Free article.
Other potential predictors, including congestion surrogates, hemodynamic and renal variables, and medical history variables, were tested. An instantaneous estimation of plasma volume at month 1 was defined and also tested. ...CONCLUSIONS: In HF complicating myocardial infa …
Other potential predictors, including congestion surrogates, hemodynamic and renal variables, and medical history variables, were tes …
Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research.
Zoccali C, Bolignano D, D'Arrigo G, Dekker FW, Fliser D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Parati G, Rossignol P, Tripepi G, Vanholder R, Wiecek A, London G; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association–European Dialysis Transplantation Association (ERA-EDTA). Zoccali C, et al. Hypertension. 2015 Jul;66(1):3-9. doi: 10.1161/HYPERTENSIONAHA.115.04801. Epub 2015 May 11. Hypertension. 2015. PMID: 25966492 Review. No abstract available.
Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.
Kiernan MS, Gregory D, Sarnak MJ, Rossignol P, Massaro J, Kociol R, Zannad F, Konstam MA. Kiernan MS, et al. JACC Heart Fail. 2015 Mar;3(3):214-23. doi: 10.1016/j.jchf.2014.11.004. JACC Heart Fail. 2015. PMID: 25742759 Free article. Clinical Trial.
OBJECTIVES: This study investigated the dose-related effect of losartan on changes in renal function using data from the HEAAL (Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan) trial. BACKGROUND: Angiotensin receptor blockers adversely affect …
OBJECTIVES: This study investigated the dose-related effect of losartan on changes in renal function using data from the HEAAL …
Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure.
Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, Tritto I, Zannad F, Girerd N. Coiro S, et al. Eur J Heart Fail. 2015 Nov;17(11):1172-81. doi: 10.1002/ejhf.344. Epub 2015 Sep 29. Eur J Heart Fail. 2015. PMID: 26417699 Free article.
The aim of this study was to assess the short-term prognostic value of B-lines after discharge from HF hospitalisation compared with other indices of haemodynamic congestion (BNP, E/e', and inferior vena cava diameter) or clinical status (NYHA class). METHODS AND RESULTS: …
The aim of this study was to assess the short-term prognostic value of B-lines after discharge from HF hospitalisation compared with other i …
Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser F, Zannad F, Rossignol P, Cachofeiro V, López-Andrés N. Martínez-Martínez E, et al. Hypertension. 2015 Oct;66(4):767-75. doi: 10.1161/HYPERTENSIONAHA.115.05876. Epub 2015 Aug 3. Hypertension. 2015. PMID: 26238446
Galectin-3 (Gal-3), a beta-galactoside-binding lectin, is associated with inflammation and fibrosis in the cardiovascular system. We herein investigated whether Gal-3 inhibition could block aldosterone-induced cardiac inflammation and fibrosis and its potenti …
Galectin-3 (Gal-3), a beta-galactoside-binding lectin, is associated with inflammation and fibrosis in the cardiovascular system …
20 results